利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.009 秒)

    CELL MODEL AND SCREENING METHOD FOR SCREENING C-FMS KINASE INHIBITORS
    18.
    发明公开
    CELL MODEL AND SCREENING METHOD FOR SCREENING C-FMS KINASE INHIBITORS 有权
    ZELLMODELL显示屏VERFAHREN ZUM筛选VON C-FMS-激酶基因

    公开(公告)号：EP2692857A4

    公开(公告)日：2014-12-10

    申请号：EP12762924

    申请日：2012-03-14

    申请人： INST PHARM & TOXICOLOGY AMMS

    发明人： WANG LILI ,  YANG SHENGQIAN ,  LONG LONG ,  XIAO JUNHAI ,  LI SONG

    IPC分类号： C12N5/00 ,  C07K14/53 ,  C12N5/09 ,  C12N9/12 ,  C12Q1/48 ,  C12R1/91

    CPC分类号： G01N33/5035 ,  C07K14/4705 ,  C07K14/7153 ,  C12Q1/485 ,  C12Y207/01112 ,  G01N2500/10

    摘要： The present invention provides a cell model and a method for screening c-Fms tyrosine kinase inhibitors. Specifically, the present invention provides a cell that expresses macrophage colony stimulating factor receptor and STAT1 protein simultaneously. The present invention further provides a method for screening c-Fms tyrosine kinase inhibitors, a method for evaluating the inhibiting activity of a compound or a composition against c-Fms tyrosine kinase, and use of the cell in screening c-Fms tyrosine kinase inhibitors. The cell model established in the present invention is sensitive, highly effective and reliable, and can be used in high-throughput screening and/or high-content screening of c-Fms tyrosine kinase inhibitors.

    摘要翻译： 本发明提供了一种用于筛选c-Fms酪氨酸激酶抑制剂的细胞模型和方法。 具体地，本发明提供同时表达巨噬细胞集落刺激因子受体和STAT1蛋白的细胞。 本发明进一步提供了筛选c-Fms酪氨酸激酶抑制剂的方法，用于评估化合物或组合物对c-Fms酪氨酸激酶的抑制活性的方法，以及该筛选c-Fms酪氨酸激酶抑制剂中该细胞的用途。 本发明建立的细胞模型是敏感，高效和可靠的，可用于c-Fms酪氨酸激酶抑制剂的高通量筛选和/或高含量筛选。

    HEXAKETIDE COMPOUND AND MEDICINAL USE THEREOF
    20.
    发明公开
    HEXAKETIDE COMPOUND AND MEDICINAL USE THEREOF 有权
    HEXAKETIDVERBINDUNG UND IHRE MEDIZINISCHE VERWENDUNG

    公开(公告)号：EP2570408A4

    公开(公告)日：2013-11-13

    申请号：EP11780054

    申请日：2011-05-16

    申请人： INST PHARM & TOXICOLOGY AMMS

    发明人： LI SONG ,  ZHONG WU ,  LIU JUAN ,  WANG LILI ,  HE KUNLUN ,  LONG LONG ,  XIAO JUNHAI ,  ZHENG ZHIBING ,  LI WEI ,  LI XIN ,  HU GUOLIANG

    IPC分类号： C07D295/03 ,  A61K31/17 ,  A61K31/5375 ,  A61P9/04 ,  A61P9/10 ,  A61P25/28 ,  A61P31/12 ,  C07C275/20 ,  C07C335/10

    CPC分类号： C07D295/215 ,  C07D295/194

    摘要： The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof; to a composition comprising a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent; and also to use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, or preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, or preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

    摘要翻译： 本发明涉及式I化合物或其异构体，药学上可接受的盐和溶剂合物; 涉及包含式I化合物或其异构体，药学上可接受的盐和溶剂化物以及药学上可接受的载体，赋形剂或稀释剂的组合物; 以及使用式I化合物或其异构体，药学上可接受的盐和溶剂化物来防治凋亡，或预防或治疗与凋亡相关的疾病或病症; 特别是用于保护心肌细胞，或预防或治疗与心肌细胞凋亡相关的疾病或病症。